Enteric Fever, Plague Vaccines From Synthetic Biology Firm Near Clinical Studies
The oral administration of synthetic thermostable vaccines that use a bacterial vector could enter clinical studies in 2019, funded by VCs interested in their use in emerging markets, where endemic and childhood diseases could yield to the new approach.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.